Cancer therapy-related interstitial lung disease.
10.1097/CM9.0000000000003149
- Author:
Chengzhi ZHOU
1
;
Haiyi DENG
2
;
Yilin YANG
1
;
Fei WANG
1
;
Xinqing LIN
1
;
Ming LIU
1
;
Xiaohong XIE
1
;
Tao LUAN
1
;
Nanshan ZHONG
1
Author Information
1. State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China.
2. KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, Guangdong 511436, China.
- Publication Type:Review
- MeSH:
Humans;
Lung Diseases, Interstitial/diagnosis*;
Neoplasms/therapy*;
Risk Factors;
Immune Checkpoint Inhibitors/adverse effects*;
Antineoplastic Agents/therapeutic use*
- From:
Chinese Medical Journal
2025;138(3):264-277
- CountryChina
- Language:English
-
Abstract:
With the increasing utilization of cancer therapy, the incidence of lung injury associated with these treatments continues to rise. The recognition of pulmonary toxicity related to cancer therapy has become increasingly critical, for which interstitial lung disease (ILD) is a common cause of mortality. Cancer therapy-related ILD (CT-ILD) can result from a variety of treatments including chemotherapy, targeted therapy, immune checkpoint inhibitors, antibody-drug conjugates, and radiotherapy. CT-ILD may progress rapidly and even be life-threatening; therefore, prompt diagnosis and timely treatment are crucial for effective management. This review aims to provide valuable information on the risk factors associated with CT-ILD; elucidate its underlying mechanisms; discuss its clinical features, imaging, and histological manifestations; and emphasize the clinical-related views of its diagnosis. In addition, this review provides an overview of grading, typing, and staging treatment strategies used for the management of CT-ILD.
